ESMO 2023: Opdivo regimen boosts bladder cancer survival

Bristol Myers Squibb (NYSE: BMY) has announced the first presentation of results from the Phase III CheckMate -901 trial involving Opdivo (nivolumab) at the 2023 European Society for Medical Oncology (ESMO) Congress.

Alongside cisplatin-based chemotherapy followed by Opdivo monotherapy, the immune checkpoint inhibitor demonstrated statistically-significant and clinically-meaningful improvements in the primary efficacy endpoints of overall survival (OS) and progression-free survival (PFS) as a first-line treatment for unresectable or metastatic urothelial carcinoma patients who are cisplatin-eligible.

With a median follow-up of approximately 33 months, treatment with Opdivo in combination with cisplatin-based chemotherapy reduced the risk of death by 22%, demonstrating a median OS of 21.7 months versus 18.9 months with chemotherapy alone.